Theravance Biopharma Financials - Benzinga

Theravance Biopharma Inc

TBPHNASDAQ

Trade with Public

Trade with Public

$17.04

0.0140.08%

Últ. Act.: Sep 23, 5:58 PM

Fusiones y adquisiciones: Theravance Biopharma (TBPH) was acquired by Zymeworks (ZYME) on Wednesday, September 23, 2026 for $929M paid in cash

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Theravance Biopharma Financials

Theravance Biopharma (TBPH) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from

Benzinga Newsdesk

PRO
Theravance Biopharma Q1 EPS $(0.10) Misses $0.03 Estimate, Sales $17.699M Beat $17.200M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.03 by 433.33 percent. This is a 62.96 percent increase over losses of $(0.27) per share

Benzinga Newsdesk

PRO
Theravance Biopharma Q4 EPS $1.15 Beats $1.02 Estimate, Sales $45.891M Miss $50.793M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.02 by 12.75 percent. This is a 2400 percent increase over losses of $(0.05) per share from

Benzinga Newsdesk

PRO
Theravance Biopharma Q3 EPS $0.07 Beats $(0.13) Estimate, Sales $19.990M Beat $19.960M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.13) by 154.69 percent. This is a 216.67 percent increase over losses of $(0.06) per share

Benzinga Newsdesk

Earnings Scheduled For November 10, 2025

Benzinga Insights

PRO
Theravance Biopharma Q2 Adj. EPS $(0.08) Beats $(0.17) Estimate, Sales $26.195M Beat $22.437M Estimate

Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52.94 percent. This is a 38.46 percent increase over losses of $(0.13) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved